ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2136

Identification of Synovial Fibroblast Subsets That Define Pathology in Rheumatoid Arthritis

Fumitaka Mizoguchi1, Kamil Slowikowski2,3, Sook Kyung Chang1, Deepak A. Rao4, Hung Nguyen1, Erika H. Noss5, Brandon E. Earp6, Philip E. Blazar6, John Wright6, Barry P. Simmons6, Nir Hacohen7,8,9, Peter A. Nigrovic1,10, Soumya Raychaudhuri2,3,11 and Michael B. Brenner1, 1Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, 4Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Divison of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 7Broad Institute of MIT and Harvard, Cambridge, MA, 8Massachusetts General Hospital, Charlestown, MA, 9Harvard Medical School, Boston, MA, 10Division of Immunology, Boston Children's Hospital, Boston, MA, 11Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: fibroblasts and rheumatoid arthritis (RA), Gene Expression

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis II

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Synovial fibroblasts play crucial roles in the pathogenesis of rheumatoid arthritis (RA). They expand as part of the pannus, mediate degradation of cartilage, amplify inflammation, and contribute to osteoclastogenesis. Considering these diverse roles of synovial fibroblasts, we hypothesized that synovial fibroblasts may consist of several subsets with distinct functions, contrary to the common view of fibroblasts as a homogeneous population. Here we sought to identify fibroblast subsets and to characterize subpopulations important in the pathology of RA.

Methods: Synovial cells were isolated by enzymatic digestion from surgical specimens from osteoarthritis (OA) and RA patients. Flow cytometry was used to separate freshly isolated fibroblasts into subpopulations based on the expression of several mesenchymal cell markers. In our initial analysis, nine fibroblast subpopulations were collected by cell sorting and subjected to further analysis by Affymetrix GeneChip Human Gene 2.0 ST microarray. To validate results, we applied low-input RNA-sequencing and single cell RNA-sequencing to independent samples. The functions of these fibroblast subsets were examined by several in vitro assays including the response to TNF stimulation and co-culture with macrophages. 

Results: Freshly isolated synovial fibroblasts were divided into several subpopulations based on the expression patterns of fibroblast markers including podoplanin, cadherin11, CD90, CD34, and CD146. The analysis of gene expression microarray data revealed 2,986 genes with significant (1% FDR) variation across fibroblast subpopulations. An independent sample of RA donors, from different joints than the original samples, and assayed via RNA-seq, showed consistent variation of these genes across fibroblast subpopulations. Pathways enriched with this variation included extracellular matrix disassembly (P=7.51e-11) and the TNF signaling pathway (P=1.96e-6). We defined distinct functional cell populations by population-specific expression of genes with well-studied functions. For example, CD34+, CD90+, cadherin11+ cells highly expressed IL-6, CCL2 and CXCL12. CD34-, CD90+, cadherin11+ cells highly expressed TNFSF11. CD34-, CD90- cells highly expressed IL-8, CXCL1, MMP-1 and MMP-3. Differential expression of several genes that mediate distinct fibroblast functions was confirmed at the protein level after culturing cells in the presence or absence of TNF. Functionally, CD34+, CD90+, cadherin11+ cells skewed macrophages into anti-inflammatory phenotype. CD34-, CD90+, cadherin11+ cells promoted osteoclastogenesis. In RA synovial tissue, the proportion of CD34-, CD90+, cadherin11+ cells was increased compared to that in OA.

Conclusion: 1) Synovial fibroblasts are composed of several subsets that are distinct in surface phenotype, transcriptional programs, and functional effects on other cell types. 2) The heterogeneity of fibroblasts and the selective expansion of particular subsets are relevant to understanding RA pathology.


Disclosure: F. Mizoguchi, None; K. Slowikowski, None; S. K. Chang, None; D. A. Rao, None; H. Nguyen, None; E. H. Noss, None; B. E. Earp, None; P. E. Blazar, None; J. Wright, None; B. P. Simmons, None; N. Hacohen, None; P. A. Nigrovic, None; S. Raychaudhuri, None; M. B. Brenner, Adheron Therapeutics, 1,Adheron Therapeutics, 5.

To cite this abstract in AMA style:

Mizoguchi F, Slowikowski K, Chang SK, Rao DA, Nguyen H, Noss EH, Earp BE, Blazar PE, Wright J, Simmons BP, Hacohen N, Nigrovic PA, Raychaudhuri S, Brenner MB. Identification of Synovial Fibroblast Subsets That Define Pathology in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/identification-of-synovial-fibroblast-subsets-that-define-pathology-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-synovial-fibroblast-subsets-that-define-pathology-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology